Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Given the broad inclusion criteria and relatively few exclusion criteria, these results are likely generalizable to a large proportion of at-risk statin-treated patients with atherosclerosis or diabetes.
“Given the broad inclusion criteria and relatively few exclusion criteria, these results are likely generalizable to a large proportion of at-risk statin-treated patients with atherosclerosis or diabetes (21).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [21]
The REDUCE-IT results were consistent across each of the primary and key secondary endpoint components and appear applicable to a substantial proportion of patients in clinical practice.
“The results were also consistent across each of the primary and key secondary endpoint components and appear to be applicable to a substantial proportion of patients in clinical practice (21).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [21]
The results of REDUCE-IT appear to be generalizable to a sizable proportion of high-risk secondary and primary prevention populations.
“The results of REDUCE-IT appear to be generalizable to a sizable proportion of high-risk secondary and primary prevention populations.14”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · see citing works
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
Roth, G. A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S. F., Abyu, G., Ahmed, M., Aksut, B., Alam, T., Alam, K., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.052 · Cited by 3,791 · see citing works
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
Self-citationSorbets, E., Greenlaw, N., Ferrari, R., Ford, I., Fox, K. M., Tardif, J., Tendera, M., Steg, P. G., & on behalf of the CLARIFY Investigators (2017) · Clinical Cardiology · doi:10.1002/clc.22730 · Cited by 52 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · see citing works
Self-citationEffects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259 · see citing works
Self-citationREDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136 · see citing works
Self-citationLawler, P. R., Kotrri, G., Koh, M., Goodman, S. G., Farkouh, M. E., Lee, D. S., Austin, P. C., Udell, J. A., & Ko, D. T. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz767 · Cited by 113 · see citing works
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.043 · Cited by 97 · see citing works
Self-citationBoden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 81 · see citing works
Self-citationChapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 68 · see citing works
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050276 · Cited by 57 · see citing works
Self-citationPeterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022937 · Cited by 46 · see citing works
Self-citationOmega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 40 · see citing works
Self-citationAmbrosy, A. P., Yang, J., Sung, S. H., Allen, A. R., Fitzpatrick, J. K., Rana, J. S., Wagner, J., Philip, S., Abrahamson, D., Granowitz, C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020377 · Cited by 32 · see citing works
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01343-7 · Cited by 24 · see citing works
Self-citationBhatt, R. D., Libby, P., Verma, S., Mason, R. P., & Bhatt, D. L. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.08.003 · Cited by 22 · see citing works
Self-citationGaba, P., Bhatt, D. L., Mason, R. P., Miller, M. J., Verma, S., Steg, P. G., & Boden, W. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.067 · Cited by 20 · see citing works
Self-citationFerrières, J., Bataille, V., Puymirat, É., Schiele, F., Simon, T., Danchin, N., & for the FAST‐MI investigators (2020) · Clinical Cardiology · doi:10.1002/clc.23437 · Cited by 18 · see citing works
Wong, N. D., Fan, W., Philip, S., Granowitz, C. B., & Toth, P. P. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.015 · Cited by 16 · see citing works
Picard, F. A., Bhatt, D. L., Ducrocq, G., Ohman, E. M., Goto, S., Eagle, K. A., Wilson, P. W. F., Smith, S. C., Elbez, Y., & Steg, P. G. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.08.031 · Cited by 14 · see citing works
Self-citationKosmopoulos, A., Verma, S., Meglis, G., Bhatt, D. L., Verma, R., Mazer, C. D., & Voisine, P. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000800 · Cited by 14 · see citing works
Self-citationImplications for REDUCE IT in clinical practice
Bittner, V. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.003 · Cited by 12 · see citing works
Beyond cardiovascular medicine: potential future uses of icosapent ethyl
Bhatt, D. L., Hull, M. A., Song, M., Hulle, C. V., Carlsson, C. M., Chapman, M. J., & Toth, P. P. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa119 · Cited by 12 · see citing works
Self-citationLakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S. A., Birudaraju, D., Cherukuri, L., Flores, F. R., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.014 · Cited by 10 · see citing works
Self-citationShen, M., Nargesi, A. A., Nasir, K., Bhatt, D. L., & Khera, R. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026075 · Cited by 9 · see citing works
Self-citationIcosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
Pareek, M., Mason, R. P., & Bhatt, D. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1954158 · Cited by 8 · see citing works
Self-citationThe potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
Derington, C. G., Bress, A. P., Herrick, J. S., Fan, W., Wong, N. D., Andrade, K., Johnson, J., Philip, S., Abrahamson, D., Jiao, L., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100345 · Cited by 8 · see citing works
Self-citationPicard, F. A., & Steg, P. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00919-2 · Cited by 8 · see citing works
Self-citationVerma, S., Kosmopoulos, A., Bhatt, D. L., FITCHETT, D. H., Ofstad, A. P., Wanner, C., Mattheus, M., Zinman, B., Lawler, P. R., & Leiter, L. A. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100510 · Cited by 7 · see citing works
Self-citationToth, P. P., Ferrières, J., Waters, M., Mortensen, M. B., Lan, N. S. R., & Wong, N. D. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1220017 · Cited by 7 · see citing works
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6 · see citing works
Zeller, M., Chague, F., Maza, M., Bichât, F., Cottin, Y., & Farnier, M. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.11.004 · Cited by 5 · see citing works
The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
Lakshmanan, S., & Budoff, M. J. (2021) · Heart International · doi:10.17925/hi.2021.15.1.7 · Cited by 4 · see citing works
Nguyen, D. T., Bilchick, K. C., Narayan, S. M., Chung, M. K., Thomas, K. L., Laurita, K. R., Vaseghi, M., Sandhu, R. K., Chelu, M. G., Kannankeril, P. J., et al. (2022) · Heart Rhythm · doi:10.1016/j.hrthm.2022.08.004 · Cited by 4 · see citing works
Egyptian practical guidance in hypertriglyceridemia management 2021
Taha, H. S. E. D., Kandil, H., Farag, N., Oraby, A., Sharkawy, M. E. E., Fawzy, F., Mahrous, H., Bahgat, J., Samy, M., Aboul, M., et al. (2021) · Egyptian Heart Journal · doi:10.1186/s43044-021-00235-9 · Cited by 1 · see citing works
Substantial Impact of Eicosapentaenoic Acid on Cardiovascular Outcomes in the REDUCE-IT Trial
Bhatt, D. L. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e3 · Cited by 1 · see citing works
Self-citationIcosapent ethyl: From the REDUCE-IT trial to clinical practice
Pedro‐Botet, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500820 · Cited by 1 · see citing works
Schuitema, P. C. E., Stam‐Slob, M. C., Visseren, F. L. J., Koopal, C., the UCC-SMART Study Group, Cramer, M. J., van der Meer, M. G., van der Harst, P., Nathoe, H. M., van Setten, J., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf091 · Cited by 1 · see citing works
Defining the Role of Icosapent Ethyl in Clinical Practice
Chatterjee, S., Hajra, A., Bandyopadhyay, D., Ghosh, R. K., & DEEDWANIA, P. C. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00402-4 · Cited by 1 · see citing works
[ON THE BEHAVIOR OF BLOOD SUGAR CURVES IN MULTIPLE SCLEROSIS PATIENTS].
Warecka, K. (1963) · PubMed
Putri, L. A. L. N. (2023) · Prosiding Workshop dan Seminar Nasional Farmasi · doi:10.24843/wsnf.2022.v02.p10
Icosapento de etilo: del ensayo REDUCE-IT a la práctica clínica
Pedro‐Botet, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500820
- Authors
- Picard, F., Bhatt, D. L., Ducrocq, G., Elbez, Y., Ferrari, R., Ford, I., Tardif, J.-C., Tendera, M., Fox, K. M., & Steg, P. G.
- Affiliations
- Hôpital Bichat-Claude-Bernard (FR)
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 73
- Issue
- 11
- Pages
- 1362-1364
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2916068410
- Cited by
- 39
- References
- 4
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 4 · 2022: 7 · 2021: 7 · 2020: 10 · 2019: 6
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Cleveland Clinic
- Boston Scientific Corporation
- Boston VA Research Institute
- Regeneron Pharmaceuticals
- Ironwood Pharmaceuticals, Incorporated
- Amarin Corporation
- Medicines Company
- Kowa Company
- Belvoir Media Group
- TauRx Pharmaceuticals
- Daiichi-Sankyo
- Eisai
- Novo Nordisk
- Servier
- Idorsia Pharmaceuticals
- Esperion Therapeutics
- St. Jude Medical
- Amarin Pharma
- Duke Clinical Research Institute
- Cilag
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- REDUCE-IT trial, icosapent ethyl, stable coronary artery disease, hypertriglyceridemia, secondary prevention, cardiovascular mortality, myocardial infarction, stroke, generalizability of trial results, omega-3 fatty acids, statin-treated patients
- MeSH terms
- Coronary Artery Disease, Humans, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
